Stock Alert: ADMA Biologics Rises 24%

(RTTNews) - Shares of ADMA Biologics Inc. (ADMA) are higher by more than 24 percent or $0.62 in Monday's morning trade at $3.14.

U.S. stocks are rising on Monday, extending gains from Friday's record highs, after the U.S. Food and Drug Administration or FDA approved emergency use of blood plasma to treat hospitalized COVID-19 patients.

ADMA Biologics manufactures specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. The company also joined the CoVIg-19 Plasma Alliance in May and has been collecting plasma from COVID-19 convalesced patients. The CoVIg-19 Plasma Alliance has been established to accelerate the development of a plasma-derived hyperimmune globulin therapy for COVID-19.

ADMA Biologics has traded in a range of $1.45 to $5.48 in the past 52 weeks.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for Smart Investing to get the latest news, strategies and tips to help you invest smarter.